Gain Therapeutics (GANX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
CIFR's 209% YTD rally and major HPC deals stand out, but rising costs and valuation concerns remain a headwind.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback